Cargando…

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions

AIM: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs). METHODS: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ivanovska Adjievska, Biljana, Boskurt, Salih, Orovcanec, Nikola, Dimovska-Jordanova, Vesna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488787/
https://www.ncbi.nlm.nih.gov/pubmed/28790803
http://dx.doi.org/10.2147/OPTH.S137380
_version_ 1783246717506813952
author Ivanovska Adjievska, Biljana
Boskurt, Salih
Orovcanec, Nikola
Dimovska-Jordanova, Vesna
author_facet Ivanovska Adjievska, Biljana
Boskurt, Salih
Orovcanec, Nikola
Dimovska-Jordanova, Vesna
author_sort Ivanovska Adjievska, Biljana
collection PubMed
description AIM: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs). METHODS: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 μm received intravitreal injection of bevacizumab. After 1 month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with <30% improvement in BCVA and CMT, two more injections were applied at 1.5-month intervals. In all other patients, further injections were applied as needed. In cases with ischemic areas of retina, laser photocoagulation of the retina was performed. RESULTS: In total, 33 patients with CRVO and 55 with BRVO were treated. After 1 year, 65 eyes (73.86%) had clinically significant improvement of BCVA (>0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2±0.95 logMAR units) to 1 year (0.75±0.6 logMAR units). Significant improvement of mean BCVA (P<0.001) was also found in BRVO, from 0.71±0.75 logMAR units at baseline to 0.28±0.5 logMAR units at 1 year. Baseline CMT was 852.21±298.20 μm for CRVO and 597.95±185.63 μm for BRVO. In both groups, there was significant decrease (P<0.001) in CMT after 1 year of treatment. Panretinal laser photocoagulation was done in 75.8% of all eyes with CRVO and sectoral photocoagulation in 49.1% of eyes with BRVO. CONCLUSION: In macular edema due to RVO, intravitreal bevacizumab provides improvement in visual acuity and reduction of macular edema in a high percentage of treated eyes after 1 year, even with low number of injections.
format Online
Article
Text
id pubmed-5488787
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-54887872017-08-08 The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions Ivanovska Adjievska, Biljana Boskurt, Salih Orovcanec, Nikola Dimovska-Jordanova, Vesna Clin Ophthalmol Original Research AIM: We aimed to evaluate the 1-year efficacy and safety of low-frequency intravitreal bevacizumab in the treatment of macular edema due to retinal vein occlusions (RVOs). METHODS: The study comprised an interventional prospective study of patients with macular edema due to central retinal vein occlusion (CRVO) or branch retinal vein occlusion, followed for 12 months. Treatment-naïve patients with reduced best-corrected visual acuity (BCVA) and central macular thickness (CMT) of at least 250 μm received intravitreal injection of bevacizumab. After 1 month, BCVA and optical coherence tomography (OCT) images of the macula were recorded. In patients with <30% improvement in BCVA and CMT, two more injections were applied at 1.5-month intervals. In all other patients, further injections were applied as needed. In cases with ischemic areas of retina, laser photocoagulation of the retina was performed. RESULTS: In total, 33 patients with CRVO and 55 with BRVO were treated. After 1 year, 65 eyes (73.86%) had clinically significant improvement of BCVA (>0.3 log of the minimum angle of resolution [logMAR] units) with average number of injections of 1.98. Improvement of mean BCVA in CRVO was significant (P=0.001) from baseline (1.2±0.95 logMAR units) to 1 year (0.75±0.6 logMAR units). Significant improvement of mean BCVA (P<0.001) was also found in BRVO, from 0.71±0.75 logMAR units at baseline to 0.28±0.5 logMAR units at 1 year. Baseline CMT was 852.21±298.20 μm for CRVO and 597.95±185.63 μm for BRVO. In both groups, there was significant decrease (P<0.001) in CMT after 1 year of treatment. Panretinal laser photocoagulation was done in 75.8% of all eyes with CRVO and sectoral photocoagulation in 49.1% of eyes with BRVO. CONCLUSION: In macular edema due to RVO, intravitreal bevacizumab provides improvement in visual acuity and reduction of macular edema in a high percentage of treated eyes after 1 year, even with low number of injections. Dove Medical Press 2017-06-21 /pmc/articles/PMC5488787/ /pubmed/28790803 http://dx.doi.org/10.2147/OPTH.S137380 Text en © 2017 Ivanovska Adjievska et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Ivanovska Adjievska, Biljana
Boskurt, Salih
Orovcanec, Nikola
Dimovska-Jordanova, Vesna
The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
title The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
title_full The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
title_fullStr The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
title_full_unstemmed The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
title_short The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
title_sort outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5488787/
https://www.ncbi.nlm.nih.gov/pubmed/28790803
http://dx.doi.org/10.2147/OPTH.S137380
work_keys_str_mv AT ivanovskaadjievskabiljana theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions
AT boskurtsalih theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions
AT orovcanecnikola theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions
AT dimovskajordanovavesna theoutcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions
AT ivanovskaadjievskabiljana outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions
AT boskurtsalih outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions
AT orovcanecnikola outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions
AT dimovskajordanovavesna outcomeoflowfrequencyintravitrealbevacizumabtherapyformacularedemainretinalveinocclusions